| Bioactivity | SRP-5051 sodium is a next-generation antisense oligonucleotide of peptide phosphorodiamidate morpholino oligomer (PPMO). SRP-5051 targeting exon 51 skipping in Duchenne muscular dystrophy (DMD)[1]. |
| Name | SRP-5051 sodium |
| Formula | C404H616N202Na30O130P30 |
| Molar Mass | 12001.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sarepta Therapeutics reports positive clinical results from phase 2 MOMENTUM study of SRP-5051 in patients with Duchenne muscular dystrophy amenable to skipping exon 51. News release. Sarepta Therapeutics. May 3, 2021. Accessed May 4, 2021. |
SRP-5051 sodium
CAS: F: C404H616N202Na30O130P30 W: 12001.37
SRP-5051 sodium is a next-generation antisense oligonucleotide of peptide phosphorodiamidate morpholino oligomer (PPMO).
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.